Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

BACKGROUND: A protective malaria vaccine will likely need to elicit both cell-mediated and antibody responses. As adenovirus vaccine vectors induce both these responses in humans, a Phase 1/2a clinical trial was conducted to evaluate the efficacy of an adenovirus serotype 5-vectored malaria vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamminga, Cindy, Sedegah, Martha, Regis, David, Chuang, Ilin, Epstein, Judith E., Spring, Michele, Mendoza-Silveiras, Jose, McGrath, Shannon, Maiolatesi, Santina, Reyes, Sharina, Steinbeiss, Victoria, Fedders, Charlotte, Smith, Kathryn, House, Brent, Ganeshan, Harini, Lejano, Jennylynn, Abot, Esteban, Banania, Glenna J., Sayo, Renato, Farooq, Fouzia, Belmonte, Maria, Murphy, Jittawadee, Komisar, Jack, Williams, Jackie, Shi, Meng, Brambilla, Donald, Manohar, Nalini, Richie, Nancy O., Wood, Chloe, Limbach, Keith, Patterson, Noelle B., Bruder, Joseph T., Doolan, Denise L., King, C. Richter, Diggs, Carter, Soisson, Lorraine, Carucci, Daniel, Levine, Gail, Dutta, Sheetij, Hollingdale, Michael R., Ockenhouse, Christian F., Richie, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189219/
https://www.ncbi.nlm.nih.gov/pubmed/22003411
http://dx.doi.org/10.1371/journal.pone.0025868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189219/
https://www.ncbi.nlm.nih.gov/pubmed/22003411
http://dx.doi.org/10.1371/journal.pone.0025868

Ejemplares similares